MIB1

(redirected from Ki-67)
Also found in: Wikipedia.

MIB1

A monoclonal antibody which recognises a formalin-fixation-resistant epitope on the cell proliferation-associated Ki-67 antigen. MIB1 is a reliable marker of cell proliferation, and can be used for image analysis of paraffin-embedded tissues; Ki-67 is a short-lived nonhistone protein expressed during the G1, S and G2/M phases of the cell cycle, but not in the G0 (resting period) phase.

Image analysis of MIB1 may be an alternative method for objectively, reproducibly and reliably classifying dysplastic changes of the cervical epithelium. Its presence is regarded as an independent prognostic indicator in breast cancer—the presence of MIB-1 is associated with a slight increased tumour aggressiveness, but is a poor indicator of prognosis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
The cancer cell biological activity was reduced, based on the estrogen receptor activity of the tumor cells and a 50 percent reduction in Ki-67. The FDA subsequently approved the use of Atossa's oral Endoxifen for this patient following her surgery under the same program.
With the rapid development of molecular biology, more and more attentions have been paid to the study of tumor markers such as Ki-67 and Topoisomerase II [alpha] (Topo II[alpha]) in breast cancer.
In the second study, Nicolas Wentzensen, MD, PhD, from the National Cancer Institute and colleagues performed a prospective observational study of 3,225 women who tested positive for HPV and underwent pi6/ Ki-67 DS and HPV16 /18 genotyping.
The proliferation of squamous epithelium plays a key role in the etiopathologic cascade and destructive pattern of this disease; thus, Ki-67 and pronuclear antigen (PCNA) are commonly used as cell-proliferation markers for cholesteatoma [2].
Proliferation index as determined by Ki-67 is known to be of prognostic importance and is known to correlate with tumour grade in RCCs.
Immunohistochemistry was performed with the following antibodies: Ki-67 (Dako clone MIB1, dilution 1:100, Agilent Technologies, Waldbronn, Germany), estrogen receptor (ER; clone SP1, F.
Hematoxylin and eosin staining and immunohistochemical markers, such as c-Kit, CD34, and Ki-67, were used to diagnose GISTs (Figure 1).
The importance of these genetic factors, Ki-67 cell proliferation marker, and p53 on the prognosis of pituitary adenomas was also evaluated.
As has been shown in the literature, P16 and Ki-67 have been the leading biomarkers for high-risk HPV infections, which can lead to cancers of the cervix.